Michael A. Mcmanus Jr. - 16 Jun 2022 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
Director
Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Issuer symbol
NVAX
Transactions as of
16 Jun 2022
Net transactions value
$0
Form type
4
Filing time
21 Jun 2022, 20:48:52 UTC
Previous filing
20 Dec 2021
Next filing
16 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise +700 +7.4% 10,101 16 Jun 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Options Exercise $0 -700 -100% $0.000000* 0 16 Jun 2022 Common Stock 700 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2 In connection with the reporting person's departure from the Board of Directors (the "Board"), the Board accelerated the vesting of 700 RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), to June 16, 2022 from June 17, 2022.